ST. HELIER, Jersey--(BUSINESS WIRE)--NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22 per share. In addition, the underwriters for the offering have a 30-day option, commencing on October 1, 2015, to purchase up to an additional 1,125,000 ordinary shares. The shares began trading on the NASDAQ Global Select Market on October 2, 2015 under the symbol “NVCR.”
Help employers find you! Check out all the jobs and post your resume.
